Abstract:CDK2, which interacts with cyclin A and cyclin E, is an important member of the CDK family. Having been proved to be associated with many diseases for its vital role in cell cycle, CDK2 is a promising target of anti-cancer drugs dealing with cell cycle disorders. In the present work, a total of 111 pyrazolo[1,5-a]pyrimidines (PHTPPs) as CDK2/cyclin A inhibitors were studied to conduct three-dimensional quantitative structure-activity (3D-QSAR) analyses. The optimal comparative molecular similarity indices analysis (CoMSIA) model shows that Q(2) = 0.516, R-ncv(2) = 0.912, R-pre(2) = 0.914, R-m(2) = 0.843, SEP = 0.812, SEE = 0.347 with 10 components using steric, hydrophobic and H-bond donor field descriptors, indicating its effective internal and external predictive capacity. The contour maps further indicate that (1) bulky substituents in R-1 are beneficial while H-bond donor groups at this position are detrimental; (2) hydrophobic contributions in the R-2 area are favorable; (3) large and hydrophilic groups are well tolerated at the R-3 position (a close H-bond donor moiety is favorable while a distal H-bond donor moiety in this area is disfavored); (4) bulky and hydrophobic features in the R-4 region are beneficial for the biological activities and (5) the 7-N-aryl substitution is crucial to boost the inhibitory activities of the PHTPP inhibitors. Finally, docking and MD simulations demostrate that PHTPP derivatives are stabilized in a 'flying bat' conformation mainly through the H-bond interactions and hydrophobic contacts. Comparative studies indicate that PHTPP derivatives fit well within the ATP binding cleft in CDK2, with the core heterocyclic ring overlapping significantly with the adenine group of ATP despite a small deflection. In comparison to numerous other inhibitors binding to the ATP pocket, PHTPP analogues follow the binding fashion of purine inhibitors of this kinase. It is anticipated that the binding mechanism and structural features of PHTPP inhibitors studied in the present work will benefit the discovery of more potent CDK2 inhibitors, and the valid pyrazolo[1,5-a]pyrimidine-7-N-yl inhibitors will soon emerge from the large number of screening programmes to enter in clinical studies.

Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.

Design, Synthesis and Biological Evaluation of 1-Phenanthryl-tetrahydroisoquinoline Derivatives As Novel P21-Activated Kinase 4 (PAK4) Inhibitors.

Design, Synthesis and Biological Evaluation of Chromone Derivatives As Novel Protein Kinase CK2 Inhibitors

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification.

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Exploring The Pivotal Role Of The Ck2 Hinge Region Sub-Pocket In Binding With Tricyclic Quinolone Analogues By Computational Analysis

Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.

Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Compounds Designs of CK2α Inhibitors Derived from Virtual Screening Hit Compounds by Computational Chemistry with Crystallography

An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.

Synthesis and evaluation of chemical linchpins for highly selective CK2α targeting

Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors

Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes

Recent Advances in the Discovery of CK2 Inhibitors

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors

Identification of Potential ATP-competitive Cyclin-Dependent Kinase 1 Inhibitors: De Novo Drug Generation, Molecular Docking, and Molecular Dynamics Simulation.

Structure-Based Design of 2-Aminopurine Derivatives As CDK2 Inhibitors for Triple-Negative Breast Cancer